Epigenomics grants Qiagen a research license and two-year option for non-exclusive, worldwide promotion rights to the mSEPT biomarker and DNA methylation technologies to detect colorectal cancer in blood

Epigenomics AG

Germany / Medical Devices and Diagnostics

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Qiagen N.V.

the Netherlands / Tools, Services, and Manufacturing

$4,966.0m on 02/25/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced